fashion -WSS

fashion

author：hotspot 2025-10-06 09:42:02 - browse：9682

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Teladoc has a new CEO, but challenges remain the same

WSS

ALS patient reclaims some autonomy thanks to wearable 'robot'

Curing rare childhood diseases will falter unless Congress steps up

Moderna says combo Covid

The 10 drugs up first for Medicare price negotiation

The system is set up to fail children with medical complexity

5 takeaways from STAT's examination of Zynex Medical

hotspot

fashion

entertainment

Medical records are filled with copy

Snackable artificial intelligence, expert AI, and the pharma industry

How to save PrEP access — and even expand it

Pharma companies must ensure equitable access to obesity drugs

How one medical school became remarkably diverse

Teladoc has a new CEO, but challenges remain the same

Cancer drug shortages should be causing more outrage

The 10 drugs up first for Medicare price negotiation

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Virtual Event: ASCO Recap, Live!

knowledge

Covid hospitalizations on the rise, Humana says

Deposition: Sackler embraced plan to conceal OxyContin’s strength

How to fix cancer clinical trials' diversity problem

Humana sues Biden admin over Medicare Advantage audit rule

Snackable artificial intelligence, expert AI, and the pharma industry

Crinetics acromegaly drug succeeds in late

hotspot

leisure time

hotspot

leisure time